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Although the role of nitric oxide (NO) in essential hypertension is still unclear, the eﬀects of long-term NO deﬁciency have not yet
been investigated during the critical juvenile period in spontaneously hypertensive rats (SHR). We aimed to analyze the eﬀects of
chronic NO synthase (NOS) inhibition on systolic blood pressure (sBP), vasoactivity, morphological changes and superoxide level
in the thoracic aorta (TA), NOS activity in diﬀerent tissues, and general biomarkers of oxidative stress in plasma of young SHR.
Four-week-old SHR were treated with NG-nitro-L-arginine methyl ester (L-NAME, 50mg/kg/day, p.o.) for 4-5 weeks. L-NAME
treatment induced a transient sBP increase only, and surprisingly, slightly inhibited endothelium-dependent relaxation of TA.
Hereby, the inhibition of NOS activity varied from tissue to tissue, ranging from the lowest in the TA and the kidney to the
highest in the brain stem. In spite of an increased sensitivity of adrenergic receptors, the maximal adrenergic contraction of TA
was unchanged, which was associated with changes in elastin arrangement and an increase in wall thickness. The production of
reactive oxygen species in the TA was increased; however, the level of selected biomarkers of oxidative stress did not change.
Our ﬁndings proved that the TA of young SHR responded to chronic NO deﬁciency by the development of adaptive
mechanisms on the functional (preserved NO-derived vasorelaxation, unincreased contraction) and molecular (preserved NOS
activity) level.
1. Introduction
An increase in the systolic blood pressure (sBP) evoked by
reduced production of endogenous nitric oxide (NO) after
NO synthase (NOS) inhibition has been already consid-
ered as a uniform response of the cardiovascular system.
In adult normotensive rats, the long-term administration
of NOS inhibitors, such as NG-nitro-L-arginine methyl ester
(L-NAME), elicits an unequivocal pattern of sustained
NO-deﬁcient hypertension [1]. Essential hypertension,
experimentally represented by spontaneously hypertensive
rats (SHR), is characterized by pathological changes similar
to alterations developed during NO-deﬁcient hypertension.
Increased vasoconstriction and oxidative stress, impaired
endothelium-dependent vasorelaxation, and abnormal car-
diovascular remodeling accompanied by arterial wall hyper-
trophy are the main hallmarks of these two experimental
models [2]. However, the origin of the abovementioned
cardiovascular disorders in SHR is still unclear. The shift
of the equilibrium of vasoactive compounds in favor of vaso-
constrictors has been suggested as a possible cause of these
disorders. Several studies speculated that the cause is a
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disturbed endogenous NO production and/or the decreased
endothelium-derived vasorelaxation in certain arteries
within the blood bed [3, 4]. On the other hand, other studies
conﬁrmed the potentiation of NO-dependent relaxation
associated with an increased NO production by the vessel
wall during developed essential hypertension [5, 6]. Never-
theless, oxidative stress is also very important in relation to
NO eﬀectivity and/or deﬁciency. The overproduction of
superoxides, found in adult SHR, could lead to the decrease
of NO bioavailability [7].
In young prehypertensive SHR, there are still limitations
in data about endothelial function and NO signalization and
the results are very often conﬂicting. We have recently dem-
onstrated a widespread participation and abundant eﬀect of
NO produced by NOS in the vasoactive responses of the tho-
racic aorta in 4-week-old prehypertensive SHR [8]. Several
other studies conﬁrmed a compensatory role of endoge-
nously produced NO against the increased vascular tone in
adult SHR [9, 10]. The chronic experiments with long-
term inhibition of NO production could help to specify the
role of NO signalization in the etiopathogenesis of essential
hypertension. Nevertheless, the eﬀect of long-term NOS
inhibition on blood pressure and vasoactivity during the
critical juvenile period has not yet been investigated in SHR
although this stage is one of the critical periods when the
increase in blood pressure could be modiﬁed [11]. The aim
of this study was to investigate the eﬀect of chronic NOS
inhibition using L-NAME in young 4-week-old SHR on
sBP and the vasoactive properties of the thoracic aorta
(TA). In the TA, we also evaluated wall thickness, elastin
arrangement, NO synthase activity, and reactive oxygen spe-
cies (ROS) formation. We also measured NO synthase activ-
ity in the left and right ventricle, kidneys, and brain stem.
Reactive oxygen metabolites, total thiols levels, and biological
antioxidant potency were measured as selected biomarkers of
oxidative stress and antioxidant status in plasma to provide
information related to the possible general redox imbalance.
2. Materials and Methods
2.1. Guide for the Use and Care of Laboratory Animals. Pro-
cedures were performed in accordance with institutional
guidelines and were approved by the State Veterinary and
Food Administration of the Slovak Republic and by Commit-
tee on the Ethics of Procedures in Animal, Clinical and others
Biomedical Experiments (permit number: EK/noh2s/14) of
the Institute of Normal and Pathological Physiology, Slovak
Academy of Sciences according to the European Convention
for the Protection of Vertebrate Animals used for Experi-
mental and other Scientiﬁc Purposes, Directive 2010/63/EU
of the European Parliament. All rats used in this study
were received from accredited breeding establishment of
the Institute of Normal and Pathological Physiology, Slovak
Academy of Sciences (permit number: SK U 14016) and were
housed under a 12 h light-12 h dark cycle, at a constant
humidity (45–65%) and temperature (20–22°C), with free
access to standard laboratory rat chow and drinking water.
The Institute of Normal and Pathological Physiology pro-
vided veterinary care. The health state of the animals was
daily monitored and appreciated according to speciﬁc criteria
used to determine when animals should be euthanized
(human endpoint). The features of the body (weight-short-
age), physiological functions (food and water intake, disequi-
librium, etc.), and social interactions (avoidance reactions,
uncoordinated movement, etc.) of the animals were included
into these criteria.
2.2. Experimental Animals and Treatments.Male 4-week-old
SHR were used in the present study. The animals were
divided into two groups of 8 animals each. The ﬁrst group
represented the control group (SHR). The second group
received L-NAME (50mg/kg per day) continuously. After
four weeks of treatment, we observed the death of one
rat as a result of the deterioration of health conditions:
disorientation, paralysis of lower extremities, deterioration
of the locomotion activity, and the presence of shivers
and bouts. The rest of the experimental animals was immedi-
ately (at latest in 4 hours) euthanized after the appearance of
any abovementioned symptoms. The animals were sacriﬁced
in the 5th week of the treatment by decapitation after brief
anesthetization with CO2, and all eﬀorts were made to min-
imize the suﬀering of the animals. The animals were then
used for functional, biochemical, and morphological inves-
tigation. The L-NAME uptake was monitored daily accord-
ing to the respective drink intake. During the experiment,
the sBP was measured once a week by the noninvasive
plethysmography method.
2.3. Physiological Study. The TA was isolated after brief
CO2 anesthetization and decapitation of the animals. The
vessels were cleaned of connective tissue and cut into
5mm length rings. The rings of the TA were vertically
ﬁxed between 2 stainless steel wire triangles and immersed
in a 20ml organ bath ﬁlled with Krebs solution (118mmol/
1 NaCl, 5mmol/l KCl, 25mmol/l NaHCO3, 1.2mmol/l
MgSO4.7H2O, 1.2mmol/l KH2PO4, 2.5mmol/l CaCl2,
11mmol/l glucose, and 0.032mmol/l CaNa2 EDTA). This
solution was oxygenated with a 95% O2 and 5% CO2 mixture
and stored at 37°C. The upper triangles were connected to the
sensors of the isometric tension (FSG-01, MDE, Budapest,
Hungary), and the changes in tension were registered by an
AD converter NI USB-6221 (National Instruments, Austin,
Texas, USA) and DEWESoft (Dewetron, Prague, Czech
Republic). The resting tension of 1 g was applied to each ring
and maintained throughout a 45 to 60min equilibration
period until stress relaxation no longer occurred.
Potassium chloride (100mmol/l) was added to the organ
bath to test the induction of receptor-independent con-
traction induced by depolarization of the smooth muscle
cells. Noradrenaline and phenylephrine were used as acti-
vators of α-adrenergic receptors of smooth muscle cells.
Concentration-dependent contractile responses of the TA
were induced by increasing doses of noradrenaline (10−10–
3× 10−5 mol/l) in a cumulative manner. Contractions were
expressed as the developed tension (g) or the percentage
of the maximum tissue responses to the agonist (demon-
strating the sensitivity to the noradrenaline). The concen-
trations of noradrenaline that produce the half-maximum
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response (EC50) were calculated from individual dose-
response curves and expressed as the negative logarithm
of the molar concentration.
The relaxant responses of the TA were followed by
phenylephrine-precontracted (10−6mol/l) arterial rings after
a stable plateau was achieved. The rings were then exposed
to cumulative doses of acetylcholine (10−10–3× 10−5 mol/l)
or sodium nitroprusside (10−10− 3× 10−5 mol/l). The maxi-
mal acetylcholine-induced (10−5mol/l) vasorelaxation of
phenylephrine-precontracted (10−6mol/l) arterial rings was
also followed before and 20min after the acute pretreatment
with L-NAME (10−4mol/l). The rate of relaxation was
expressed as a percentage of the contractile agonist-induced
contraction. The concentrations of acetylcholine that pro-
duced a 50% inhibition of contraction (IC50) were calculated
from individual dose-response curves and expressed as the
negative logarithm of the molar concentration.
2.4. Determination of NO Synthase Activity. Activity of NOS
was measured by conversion of radioactive [3H]-L-arginine
(Amersham, UK) to [3H]-L-citrulline. The activity of NOS
was measured in 20% homogenates prepared in Tris-HCl
with the addition of protease inhibitors. The homogenates
were centrifuged at 5000 rpm, 10min at 4°C. Samples were
measured in duplicate. The reaction mixture (0.5M Tris
pH7.4; 10mmol/l NADPH; 20mmol/l CaCl2 and MgCl2;
100μmol/l L-arginine; 1mg/ml calmodulin; 1 : 1 FAD/FMN;
radiolabeled L-arginine; 50mmol/l BH4; distilled water)
and the homogenates (50μl) were incubated 6min at 37°C.
After incubation, the reaction was initiated by addition of
the reaction mixture (50μl) to the samples. The reaction
was stopped after 20min by the addition of a solution with
1mmol/l L-citrulline in 0.02M HEPES, 2mmol/l EDTA,
and 2mmol/l EGTA. A 1ml aliquot from the sample was
applied to a Dowex column and cycled with 1.5ml distilled
water. Subsequently, the product (samples with ECOLITE
scintillation ﬂuid) was detected on the Tri-Carb 2910
TR (PerkinElmer) scintillation counter. NOS activity was
expressed as pkat/g of proteins.
2.5. Detection of ROS Formation in the Aorta Using
Dihydroethidium (DHE) Fluorescent Dye. Aortic ring sam-
ples (5mm) were prepared in Tissue-Tek O.C.T. compound,
and cryosections (30μm) were prepared using a Leica
CM1950 cryostat and mounted onto glass slides. Dihy-
droethidium (DHE, Molecular Probes) oxidation-sensitive
ﬂuorescent dye was added to the slides at a ﬁnal concentra-
tion of 10μmol/l (stock solution: 10mmol/l in DMSO), and
samples were incubated at 37°C for 30min in the dark as pre-
viously described by Oliveira et al. [12]. The production of
ROS in the cell nucleus and DHE ﬂuorescence formation
was halted by placing the microscope slides on ice. Samples
were detected by ﬂuorescence microscopy using a Nikon
Eclipse Ti-E and NIS-Elements AR program with excitation
510nm/emission 595nm. Quantiﬁcation of DHE ﬂuores-
cence intensity was analyzed using ImageJ software.
The measuring of ROS with ﬂuorescent probes could also
have some challenges and limitations [13]. In red ﬂuores-
cence measurements, DHE ﬂuorescent dye can react on two
types of products: ethidium (E+) and 2-hydroxyethidium
(2-OH-E+). They have similar ﬂuorescent spectra charac-
teristics, and HPLC analysis is required for the proper esti-
mation of superoxide production. The measurements of
ﬂuorescent increase due to the oxidation of DHE providing
only the general information on redox homeostasis disrup-
tion. Nevertheless, ﬂuorescent detection of dihydroethidium
oxidative ﬂuorescence microtopography (DHE cryo staining)
is a usual technique to assess vascular ROS formation [14].
2.6. Determination of Wall Thickness and Elastin Detection.
Aortic sections were detected by ﬂuorescence microscopy.
Wall thickness (tunica intima+ tunica media) of the TA
was determined, and the values were measured using ﬂuores-
cence microscopy.
Native tissue autoﬂuorescence is a widespread phe-
nomenon in which intrinsic biomolecules, such as collagen
and elastin in the aorta, act as endogenous ﬂuorophores.
The elastin in the TA media was detected by autoﬂuores-
cence (ex 488nm/em 510nm) using a Nikon Eclipse Ti-E
ﬂuorescence microscope.
2.7. Determination of Plasma Biomarkers. The reactive
oxygen metabolites (ROM) assay for hydroperoxides is a
spectrophotometric test that determines the concentration
of hydroperoxides. The hydroperoxides in plasma react with
a chromogenic substrate to develop a colored derivative. The
assay (dROMs) was obtained from Diacron International
(Grosseto, Italy).
The biological antioxidant potency (BAP) antioxidant
assay is a test that determines the total antioxidant status
of plasma. The BAP assay is based on the reduction of a
colored solution containing ferric ions by antioxidants in
plasma. The assay was obtained from Diacron International
(Grosseto, Italy).
The total thiol levels (TTL) assay is based on the ability of
free thiol groups to develop a colored complex when reacted
with 5,5-dithiobis-2-nitrobenzoic acid (DTNB). The color
intensity is directly related to the thiol groups which are not
aﬀected by oxidation. The assay was obtained from Rel Assay
Diagnostics (Gaziantep, Turkey).
All plasma biomarkers were measured using a UniCel
DxC 800 (Beckman-Coulter, Woerden, Netherlands) clinical
autoanalyzer.
2.8. Statistical Analysis. The data were expressed as the
means± S.E.M. For the statistical evaluation of diﬀerences
between groups, a one-way analysis of variance (ANOVA)
with a Bonferroni post hoc test and paired t-test was used.
The diﬀerences between means were considered signiﬁcant
at p < 0 05.
2.9. Drugs. The following drugs were used for analyses: acetyl-
choline (Sigma-Aldrich, St Louis, Missouri, USA), NG-nitro-
L-arginine methyl ester (Sigma-Aldrich), noradrenaline
(Zentiva, Czech Republic), phenylephrine (Sigma-Aldrich),
potassium chloride (Slavus, Slovak Republic), and sodium
nitroprusside (Sigma-Aldrich).
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3. Results
3.1. Systolic Blood Pressure, Biometric Parameters, and
Biomarkers of Oxidative Stress. Changes in the systolic blood
pressure (sBP) were monitored during the experiment in
young SHR. The sBP was signiﬁcantly decreased (SHR:
113.4± 1.9mmHg, SHR+L-NAME: 106.6± 1.6mmHg, p <
0 05) after the 1st week and signiﬁcantly increased (SHR:
137.8± 1.7mmHg, SHR+L-NAME: 150.6± 2.5mmHg, p <
0 001) after the 3rd week of L-NAME treatment; however,
at the end of the treatment, there were no diﬀerences in
sBP between the two groups (SHR: 154.4± 3.8mmHg,
SHR+L-NAME: 152.1± 3.9mmHg, Figure 1).
Heart weight, kidney weight, and body weight and their
relative ratio are shown in Table 1. There was a signiﬁcant
decrease in body weight after L-NAME treatment (p <
0 001). The heart weight/body weight as well as the kidney
weight/body weight ratio was signiﬁcantly increased in the
L-NAME group (p < 0 001).
ROM, BAP, and TTL measurements from the plasma
samples revealed no changes after chronic treatment with
L-NAME (Table 1).
3.2. The Vasoactive Responses of the Thoracic Aorta. Chronic
treatment with L-NAME signiﬁcantly reduced the contrac-
tile response to KCl (p < 0 001) compared to the control
SHR (data not shown). Cumulative application of nor-
adrenaline (10−10–3× 10−5 mol/l) induced vasoconstriction
in a concentration-dependent manner. Although the dose-
dependent curve of noradrenaline was shifted to the left
(10−9–10−7mol/l; p < 0 05, p < 0 01, and p < 0 001) in the
L-NAME group (n = 7; Figure 2(a)), the maximal force
of the contraction was not changed compared with the con-
trol SHR (n = 8). The changes in active tension correlated
with alterations in sensitivity of the smooth muscle cells
to exogenous noradrenaline. NOS inhibition by L-NAME
signiﬁcantly shifted the dose-dependent curve to the left;
the curve is expressed as a percentage of the maximal vaso-
constriction (p < 0 05, p < 0 01, and p < 0 001; Figure 2(b)).
Moreover, EC50 values were signiﬁcantly increased in the
L-NAME group (8.44± 0.17, p < 0 01) compared to the
untreated group (7.79± 0.06).
The application of acetylcholine (10−10–3× 10−5 mol/l)
evoked a concentration-dependent vasorelaxation of the
precontracted TA with phenylephrine (10−6mol/l). Chronic
treatment with L-NAME initiated a signiﬁcant, but mild,
inhibition of acetylcholine-induced vasorelaxation (p < 0 05,
p < 0 01) compared with the control group (Figure 3(a)).
While the maximal relaxant response in control SHR
(n = 8) reached 87.02± 5.85%, the response reached 64.6±
5.75% in the L-NAME group (n = 7), which represented
a surprisingly high percentage of vasorelaxation with
regard to chronic inhibition of endogenous NO production
by L-NAME. Our data showed no signiﬁcant diﬀerence
in IC50 values between the control SHR and L-NAME
groups (SHR: 7.05± 0.29, SHR+L-NAME: 7.91± 0.39). The
endothelium-independent vasorelaxation of the TA was
induced by cumulative doses of the NO donor sodium nitro-
prusside (10−10–3× 10−5 mol/l). Compared with the control
group (n = 8), L-NAME treatment (n = 7) signiﬁcantly
increased the vasoactive response to exogenous NO; not only
a signiﬁcant diﬀerence of maximal reached vasorelaxation
(p < 0 05, SHR: 104.02± 1.49%, SHR+L-NAME: 110.6±
2.88%) but also a shift of the dose-dependent curve to
the left was observed (3× 10−8–10−5mol/l, Figure 3(b)).
Because the notable residual acetylcholine-induced vaso-
relaxation was recorded in the L-NAME group, the arteries
from both groups were acutely pretreated with L-NAME
(10−4mol/l). We investigated the modulation eﬀects of L-
NAME on contractile responses induced by phenylephrine
(10−6mol/l) as well as on the vasorelaxation responses
evoked by a maximal dose of acetylcholine (10−5mol/l,
Figure 4). The acute L-NAME pretreatment induced a signif-
icant increase in phenylephrine-induced contraction in both
groups (p < 0 01, p < 0 001). Moreover, after acute pretreat-
ment with L-NAME, we observed an inhibition of the vaso-
relaxation responses to acetylcholine not only in the control
(n = 8, p < 0 001) but also in the L-NAME group (n = 7,
p < 0 01). These results proved the presence of endogenous
NO synthesis even after the long-term nonspeciﬁc NOS
inhibition by L-NAME.
3.3. NO Synthase Activity. Chronic treatment with L-NAME
induced a signiﬁcant decrease in NOS activity in all the mon-
itored tissues. However, the degree of preserved NOS activity
varied from tissue to tissue: from lowest in the brain stem to
highest in the TA and in the kidney (Figure 5).
3.4. Detection of ROS Formation, Elastin Arrangement, and
Wall Thickness in the TA. L-NAME treatment signiﬁcantly
increased the formation of ROS by 20.8% (24.52± 0.771 int/
area, n = 7) compared to the control group (20.3± 0.664
int/area, n = 8, p < 0 01, Figures 6(a) and 6(b)). Elastin is a
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Figure 1: Time course of systolic blood pressure in control SHR and
in SHR treated with L-NAME for 4-5 weeks. SHR: control group
(n = 8); SHR+L-NAME: SHR treated with L-NAME (n = 7). Data
are expressed as the mean± S.E.M. ∗p < 0 01 versus SHR; ∗∗∗p <
0 001 versus SHR.
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Table 1: General cardiovascular parameters and biomarkers of oxidative stress in young SHR after chronic NO synthase inhibition.
n
BW
(g)
HW
(mg)
HB
(mg/g)
KW
(mg)
KB
(mg/g)
ROM
(IU/l)
TTL
(μmol/l)
BAP
(meq/l)
SHR 8 248± 9.8 995.5± 42.3 4.0± 0.1 1829.7± 75.4 7.4± 0.1 297± 5 323± 15 2619± 37
SHR+L-NAME 7 180.4± 9.1∗∗∗ 1026.3± 110.0 5.3± 0.1∗∗∗ 1593.4± 99.7 8.8± 0.2∗∗∗ 314± 27 278± 18 2708± 130
n: number of rats; BW: body weight; HW: heart weight; HB: heart weight/body weight ratio; KW: kidney weight; KB: kidney weight/body weight ratio; ROM:
reactive oxygen metabolites; TTL: total thiol levels; BAP: biological antioxidant potency. Values are the mean ± S.E.M. ∗∗∗ p < 0 001 versus SHR.
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Figure 2: Concentration-response curves for exogenous noradrenaline expressed in grams (a) and as percent values of the maximum tissue
response to noradrenaline (b). SHR: control group (n = 8); SHR+L-NAME: SHR treated with L-NAME (n = 7). Values are the mean± S.E.M.
∗p < 0 05; ∗∗p < 0 01; ∗∗∗p < 0 001 versus SHR.
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Figure 3: Endothelium-dependent relaxation evoked by acetylcholine (a) and endothelium-independent relaxation evoked by sodium
nitroprusside (b) administration. SHR: control group (n = 8), SHR+L-NAME: SHR treated with L-NAME (n = 7). Values are the mean±
S.E.M. ∗p < 0 05, ∗∗p < 0 01 versus SHR.
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highly elastic protein in the connective tissue that can resume
its shape after stretching or contracting. Elastin arrangement
was also altered after L-NAME treatment (Figures 6(c)
and 6(d)). The area between elastin lines was increased,
and few loops were observed in the tunica media and tunica
intima in the L-NAME group, which could correlate with
arterial wall hypertrophy: L-NAME-treatment induced
22.3% increase in wall thickness (70.63± 2758μm, n = 7)
compared to the untreated group (58.75± 2.518μm, n = 8,
p < 0 01; Figures 6(e) and 6(f)).
4. Discussion
Permanently increased sBP is developed gradually in SHR; in
3–5-week-old SHR, it does not diﬀer from the age-matched
normotensive rats. From 6 weeks of age, it becomes higher,
and continual increasing of sBP is stopped after about 36
weeks of the age [15–17]. In this study, chronic L-NAME
treatment in young SHR induced a transient increase in
sBP in the 3rd week of treatment. In the 5th week of NO inhi-
bition, there were no sBP diﬀerences in comparison with the
control group, despite deteriorating health conditions, that is,
disorientation, paralysis of lower extremities, and body
weight loss. In adult SHR, Ono et al. [18] and Benter et al.
[19] demonstrated that 2- to 4-week-long L-NAME treat-
ment caused a sustained increase in malignant hypertension,
that is, rapid weight loss and organ malformation. Several
authors proved the existence of functional damage to the
myocardium (ﬁbrosis and cardiac infarction) and the kidney
(proteinuria and nephrosclerosis) after L-NAME treatment,
often with fatal results associated with myocardial infarction
and cerebrovascular accidents [18]. In association with the
morphological changes, the relative weight ratio of organs
could also be altered. In our experiment, both the heart
weight/body weight and the kidney weight/body weight
ratios were signiﬁcantly higher after L-NAME treatment.
The observed hypertrophy could be attributed to lower body
weight of the SHR, which is speciﬁc for this strain [9], and it
was even more noticeable after the endogenous NO inhibi-
tion. However, we showed that the inhibition of NOS activity
was not developed to the same degree in the tissues. A degree
of preserved NOS activity varied between tissues: 13.7% in
the brain stem, 22.1% in the left ventricle, 23.2% in the right
ventricle, 64.6% in the thoracic aorta, and 68.4% in the kid-
neys. Our ﬁndings suggested that, in young SHR, the chronic
inhibition of NO levels evoked negative and malignant
changes. However, contrary to the case in adult rats, this
occurred without developing a steadily increased sBP and a
crucial decrease in NO levels in the cardiovascular system.
In the present study, we evaluated the vasoactive proper-
ties of the TA which represents an elastic type of the artery.
Chronic L-NAME treatment signiﬁcantly increased sensitiv-
ity of the adrenergic receptors; on the other hand, the maxi-
mal absolute contraction was not aﬀected (Figures 2(a) and
2(b)). Moreover, we demonstrated that the vasoconstrictor
response induced by depolarization of smooth muscle cells
by KCl was signiﬁcantly decreased. The treatment with L-
NAME decreased or did not change the contractile power
of smooth muscle cells in the TA. In our previous study, we
demonstrated that, in young normotensive Wistar rats, con-
tinuous 6-week administration of L-NAME resulted in a
reduced adrenergic contraction of the TA [20]. In young nor-
motensive rats, the long-term NO blockage upregulated the
endogenous vasoconstrictor system and probably triggered
an adaptive mechanism: the downregulation of the con-
tractile response to exogenous vasoconstrictors. Addition-
ally, Oliver et al. [21] demonstrated that, after chronic
inhibition of NO synthesis, adaptive mechanisms associated
with diminished sensitivity to α-adrenergic vasoconstric-
tion accompanied by increased β-adrenergic vasodilation
occurred in the TA of normotensive WKY rats. On the other
hand, Oliver et al. [22] demonstrated that in the TA of SHR
the ratio of α-adrenergic and β-adrenergic receptors was
changed and proved an age-correlated increased sensitivity
of α-adrenergic receptors in 6- to 16-week-old SHR. Our
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L-NAME (10−4mol/l) on vasoactive responses induced by
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Figure 5: The evaluation of NO synthase activity in diﬀerent tissues.
RV: right ventricle; LV: left ventricle; TA: thoracic aorta; BS: brain
stem; KD: kidney. SHR: control group (n = 8); SHR+ L-NAME:
SHR treated with L-NAME (n = 7). Values are the mean± S.E.M.
∗∗∗p < 0 001 versus SHR.
6 Oxidative Medicine and Cellular Longevity
ﬁnding of the increased TA sensitivity to noradrenaline
after L-NAME treatment could be associated with this phe-
nomenon and ﬁts the age-dependent pathological changes
of adrenergic receptors occurred in SHR.
In diﬀerent normotensive rat models (Wistar and
Sprague-Dawley), long-term NO deﬁciency revealed myo-
cardial and arterial structural alterations such as necrosis,
ﬁbrosis, lipid deposition increased the production of extra-
cellular matrix and aortic stiﬀening [23–26]. The changes
in the arrangements of arterial wall components (collagen
ﬁbers, elastin ﬁlaments, and extracellular matrix) evoked
by NO deﬁciency may compromise the contractile func-
tion of smooth muscle cells [27]. On the other hand, other
studies conﬁrmed that, in adult hypertensive NO-defective
Wistar rats as well as SHR, the wall thickness of conduit
arteries was increased, and an increased adrenergic contrac-
tion as a response of an increased smooth muscle mass of
the arterial wall was followed [28–30]. In this study, we deter-
mined that the TA of L-NAME-treated animals underwent
structural changes and the thickness of the arterial wall
as well as the changes in the elastin arrangement was con-
ﬁrmed. It was accompanied by unchanged (noradrenaline)
or decreased (KCl) absolute contractility and increased sensi-
tivity of adrenergic receptors. Thus, the ﬁnal contractile
properties of the TA were formed by several mutual and/or
contradictory processes. In young prehypertensive SHR,
(a)
A M
E
(b)
(c) (d)
(e) (f)
Figure 6: ROS production and structural changes (elastin arrangement and wall thickness) in the TA after L-NAME treatment in young SHR.
DHE ﬂuorescence detection (ex 540 nm/em 590 nm) was used to assess vascular redox homeostasis disruption in aortic cryosections, where
ROS formation was determined by calculating the intensity (density/area) (a, b). Elastin autoﬂuorescence (ex 488 nm/em 510 nm) was
detected using ﬂuorescence microscopy of aortic cryosections (c, d). Wall thickness: tunica intima + tunica media was determined in μm
(e, f). E: endothelium; M: tunica media; A: adventitia; SHR: control group (n = 8); SHR+L-NAME: SHR treated with L-NAME (n = 7).
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unlike in young Wistar rats, the chronic NO deﬁciency can
modify the adaptive properties of the TA since the increased
sensitivity to noradrenaline was observed. Hereby, unlike
in adult SHR, the unincreased absolute force of the con-
tractile responses is in a good consent with adaptive abilities
of this vessel.
In this study, we conﬁrmed 80% endothelium-dependent
relaxation of the TA to acetylcholine in control SHR. The
chronic inhibition of endogenously produced NO after L-
NAME treatment stimulated only partial reduction of vaso-
relaxation; the inhibition of the maximal vasorelaxation
response was surprisingly 35% (Figure 3(a)). Moreover, this
ﬁnding was supported by biochemical measurement of
NOS activity in the TA, which showed only 35.4% inhibition
after L-NAME treatment (Figure 5). On the other hand, pre-
vious papers demonstrated that L-NAME treatment in adult
SHR signiﬁcantly inhibited endothelium-derived vasorelax-
ation [19, 31] and a similar reduction of acetylcholine-
induced vasorelaxation after chronic L-NAME treatment
was also demonstrated in adult and young normotensive rats
[20, 32, 33]. To determine if preserved relaxation was medi-
ated by endogenous NO, we acutely pretreated the TA with
L-NAME (10−4mol/l) (Figure 4). A signiﬁcantly blocked
relaxation response to acetylcholine and a potentiated con-
tractile response to phenylephrine in the chronically treated
L-NAME group suggested that there was a suﬃcient amount
of physiologically active NO contributing to the maintenance
of the relaxant responses, even after chronic nonspeciﬁc NOS
inhibition. It also correlated with an unchanged sBP at the
end of the treatment (blood pressure was increased only in
the 3rd week). Several studies conﬁrmed that conduit arteries
in SHR could have undamaged endothelium-dependent
vasorelaxation and enhanced endogenous production of
NO [5]. Moreover, our previous study showed that NO con-
tributed to the vasorelaxation responses of the TA in the pre-
hypertensive SHR signiﬁcantly more than in age-matched
Wistar rats [8].Thus, we can suggest that in young SHR, the
treatment with L-NAME was not able to fully inhibit the
increased NO production in the TA. On the other hand, we
might also assume that certain adaptive mechanisms could
be triggered in young SHR. Since we also observed an
increased maximal response as well as sensitivity to sodium
nitroprusside after L-NAME administration, we may con-
sider as a compensatory mechanism the increased sensitivity
of smooth muscle cells to NO itself (Figure 3(b)). Moreover,
recent study has proven that the prehypertensive phase of
SHR is associated with an increased production and activity
of asymmetric dimethyl L-arginine (ADMA), which is an
endogenous inhibitor of NOS [34, 35]. Cheng et al. [36] dem-
onstrated that continuous 6-week L-NAME treatment
caused an additional increase in the plasma levels of ADMA
in these rats. In the cardiovascular system, the principle of
negative feedback regulation is often present. Kristek et al.
[37] and Dovinova et al. [38] showed that, in SHR, an
increased NO concentration may cause an inhibitory eﬀect
on NOS activity. Pechánová et al. [28] determined a negative
correlation between endothelial NOS expression and activity:
an increased expression resulted in an activity reduction
in order to maintain a constant level of NO in the
cardiovascular system. Cebova et al. [39] showed that
although the long-term NO inhibition with L-NAME in
adult WKY inhibited the NOS activity in the TA, it had no
impact on the NOS protein expression. Regarding these facts,
we speculated that only partially inhibited acetylcholine-
induced vasorelaxation in the TA could be a negative feed-
back response of the cardiovascular system. If the level of
ADMA as an endogenous NOS inhibitor is higher in young
SHR, an addition of exogenous NOS inhibitor (L-NAME)
could stimulate a compensatory (maybe tissue-speciﬁc)
response and attenuate inhibition of NOS activity.
Kröller-Schön et al. [40] and Wenzel et al. [41] declared
that, in the control (healthy) tissue, treatment with the NOS
inhibitor (L-NAME) led to the inhibition of NO formation
from intact NOS, resulting in the increased superoxide pro-
duction. In the pathological stages, one of the mechanisms
of the increased oxidative stress is the formation of
uncoupled NOS, which produces superoxide instead of NO.
Javkhedkar et al. [42], Bhatt et al. [3], and Chen et al. [43]
conﬁrmed the formation of uncoupled NOS in SHR, which
subsequently led to the overproduction of superoxide. As
such, the treatment with L-NAME induces the direct inhibi-
tion of uncoupled NOS, which leads to the decrease in super-
oxide production and oxidative stress in the diseased tissue
[3, 40, 41]. Nevertheless, in our experiment, we determined
that the chronic treatment with L-NAME induced an
increase of ROS approximately 21% (and not a decrease) in
the TA. It seems that the NOS enzyme in the TA of SHR is
suﬃciently intact to ensure a functional NO pathway. This
suggestion that was also supported by the preserved (control
group) or mildly inhibited (treated group) vasorelaxation.
However, several mechanisms and pathways could be
responsible for the production of free radicals in the cardio-
vascular system. In general, nicotinamide adenine dinucleo-
tide phosphate oxidase (NOX) acts as the primary source of
superoxide anions and H2O2 in the vessel wall. NOX-
derived ROS then act as “kindling” and activate secondary
(uncoupled eNOS, xanthine oxidase) and tertiary (mitochon-
drial) sources of ROS, which contribute to the “bonﬁre” of
radicals and oxidative stress seen at later stages of diseases
[44]. An increased NOX activity can be inﬂuenced by NO
production. It has been showed that endogenous NO attenu-
ated NADPH oxidase-dependent superoxide production and
that after L-NAME treatment a signiﬁcant increase in aortic
p47phox (a main regulator of NOX activation expression)
was observed [45]. So it seems that vascular oxidative stress
might be suppressed by NO donors and, on the other hand,
the decreased NO levels could increase NADPH oxidase
activation in vascular tissue. ROS have a very short half-life
and cannot be measured in plasma or serum samples. There-
fore, derivatives of reactive oxygen metabolites (d-ROM) as
a proxy for ROS production and total thiol levels (TTL) of
proteins in serum as a proxy for the redox control status
were measured [46]. BAP test provides a useful assessment
of antioxidant activity of blood plasma. However, our
results showed that after L-NAME treatment, there were
no diﬀerences in ROM, TTL, and BAP. Therefore, it seems
that chronic NO deﬁciency in young SHR probably did not
lead to disorder in general redox status, and followed
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functional malfunctions could rather be a cause of tissue-
speciﬁc impairment.
Our ﬁndings proved that chronic NO deﬁciency, initiated
in the prehypertensive period of the SHR, led to the develop-
ment of adaptive vasoactive mechanisms. TA of young SHR
responded to chronic L-NAME treatment by the develop-
ment of adaptive mechanisms on the functional (preserved
NO-derived vasorelaxation, unincreased contraction) and
molecular (preserved NOS activity) level. Our ﬁndings also
conﬁrmed the structural remodeling (wall thickness, changes
in elastin arrangement) and increased superoxide production
in the TA; however, the selected biomarkers of the oxidative
stress in plasma remained unchanged.
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